Evolution of commercially available compounds for HTS.

Over recent years, an industry of compound suppliers has grown to provide drug discovery with screening compounds: it is estimated that there are over 16 million compounds available from these sources. Here, we review the chemical space covered by suppliers' compound libraries (SCL) in terms of compound physicochemical properties, novelty, diversity, and quality. We examine the feasibility of compiling high-quality vendor-based libraries avoiding complicated, expensive compound management activity, and compare the resulting libraries to the ChEMBL data set. We also consider how vendors have responded to the evolving requirements for drug discovery.

[1]  M. R. Senger,et al.  Filtering promiscuous compounds in early drug discovery: is it a good idea? , 2016, Drug discovery today.

[2]  M. Congreve,et al.  A 'rule of three' for fragment-based lead discovery? , 2003, Drug discovery today.

[3]  Tudor I. Oprea,et al.  Pursuing the leadlikeness concept in pharmaceutical research. , 2004, Current opinion in chemical biology.

[4]  Raymond J Winquist,et al.  The fall and rise of pharmacology--(re-)defining the discipline? , 2014, Biochemical pharmacology.

[5]  S. Rees,et al.  Principles of early drug discovery , 2011, British journal of pharmacology.

[6]  Florian Nigsch,et al.  Recent trends and observations in the design of high-quality screening collections. , 2011, Future medicinal chemistry.

[7]  Sarah R. Langdon,et al.  Scaffold Diversity of Exemplified Medicinal Chemistry Space , 2011, J. Chem. Inf. Model..

[8]  Hélène Decornez,et al.  Computational Techniques to Support Hit Triage , 2015 .

[9]  Tudor I. Oprea,et al.  The Design of Leadlike Combinatorial Libraries. , 1999, Angewandte Chemie.

[10]  D. Bojanic,et al.  Impact of high-throughput screening in biomedical research , 2011, Nature Reviews Drug Discovery.

[11]  John M. Barnard,et al.  Identification of diverse database subsets using property-based and fragment-based molecular descriptions , 2002 .

[12]  Miklos Feher,et al.  Property Distributions: Differences between Drugs, Natural Products, and Molecules from Combinatorial Chemistry , 2003, J. Chem. Inf. Comput. Sci..

[13]  I. Kola,et al.  Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.

[14]  J. Baell,et al.  New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. , 2010, Journal of medicinal chemistry.

[15]  Hui Liu,et al.  Comparative analyses of structural features and scaffold diversity for purchasable compound libraries , 2017, Journal of Cheminformatics.

[16]  Andrew L Hopkins,et al.  The Joint European Compound Library: boosting precompetitive research. , 2015, Drug discovery today.

[17]  Alexander Chuprina,et al.  Drug- and Lead-likeness, Target Class, and Molecular Diversity Analysis of 7.9 Million Commercially Available Organic Compounds Provided by 29 Suppliers , 2010, J. Chem. Inf. Model..

[18]  David H. Drewry,et al.  New Compound Sets Identified from High Throughput Phenotypic Screening Against Three Kinetoplastid Parasites: An Open Resource , 2015, Scientific Reports.

[19]  L. L. Elkin,et al.  Just-in-Time Compound Pooling Increases Primary Screening Capacity without Compromising Screening Quality , 2015, Journal of biomolecular screening.

[20]  David J. Nicholls,et al.  Impact of a five-dimensional framework on R&D productivity at AstraZeneca , 2018, Nature Reviews Drug Discovery.

[21]  Kelly Chibale,et al.  Recent approaches to chemical discovery and development against malaria and the neglected tropical diseases human African trypanosomiasis and schistosomiasis. , 2014, Chemical reviews.

[22]  C. Harris,et al.  How large does a compound screening collection need to be? , 2008, Combinatorial chemistry & high throughput screening.

[23]  Oliver Gassmann,et al.  Changing R&D models in research-based pharmaceutical companies , 2016, Journal of Translational Medicine.

[24]  J. Scannell,et al.  Diagnosing the decline in pharmaceutical R&D efficiency , 2012, Nature Reviews Drug Discovery.

[25]  Andrew Bell,et al.  Shaping a Screening File for Maximal Lead Discovery Efficiency and Effectiveness: Elimination of Molecular Redundancy , 2012, J. Chem. Inf. Model..

[26]  Roberto Todeschini,et al.  Molecular descriptors for chemoinformatics , 2009 .

[27]  Adam Nelson,et al.  Expansion of chemical space for collaborative lead generation and drug discovery: the European Lead Factory Perspective. , 2015, Drug discovery today.

[28]  Ian A. Watson,et al.  Rules for identifying potentially reactive or promiscuous compounds. , 2012, Journal of medicinal chemistry.

[29]  Christopher P Austin,et al.  Quantitative analyses of aggregation, autofluorescence, and reactivity artifacts in a screen for inhibitors of a thiol protease. , 2010, Journal of medicinal chemistry.

[30]  Lorenz M Mayr,et al.  The Future of High-Throughput Screening , 2008, Journal of biomolecular screening.

[31]  Christopher B. Cooper,et al.  Development of Mycobacterium tuberculosis whole cell screening hits as potential antituberculosis agents. , 2013, Journal of medicinal chemistry.

[32]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings , 1997 .

[33]  Anthony D. Keefe,et al.  DNA-encoded chemistry: enabling the deeper sampling of chemical space , 2016, Nature Reviews Drug Discovery.

[34]  Nicolas Foloppe,et al.  Drug-like Annotation and Duplicate Analysis of a 23-Supplier Chemical Database Totalling 2.7 Million Compounds , 2004, J. Chem. Inf. Model..

[35]  G. Bemis,et al.  The properties of known drugs. 1. Molecular frameworks. , 1996, Journal of medicinal chemistry.

[36]  Robin B. Gasser,et al.  Screening of the ‘Open Scaffolds’ collection from Compounds Australia identifies a new chemical entity with anthelmintic activities against different developmental stages of the barber's pole worm and other parasitic nematodes , 2017, International journal for parasitology. Drugs and drug resistance.

[37]  Matthew D. Troutman,et al.  Experimental Screening Strategies to Reduce Attrition Risk , 2015 .

[38]  Dragos Horvath,et al.  Chemical Data Visualization and Analysis with Incremental Generative Topographic Mapping: Big Data Challenge , 2015, J. Chem. Inf. Model..

[39]  W Frank An,et al.  Cell-Based Assays for High-Throughput Screening , 2010, Molecular biotechnology.

[40]  M. Prunotto,et al.  Opportunities and challenges in phenotypic drug discovery: an industry perspective , 2017, Nature Reviews Drug Discovery.

[41]  Jonathan B. Baell,et al.  Broad Coverage of Commercially Available Lead-like Screening Space with Fewer than 350, 000 Compounds , 2013, J. Chem. Inf. Model..

[42]  Stephen D. Pickett,et al.  Research Papers) Design of a Compound Screening Collection for use in High Throughput Screening , 2004 .

[43]  Ramaswamy Nilakantan,et al.  A novel approach to combinatorial library design. , 2002, Combinatorial chemistry & high throughput screening.

[44]  D. Horvath,et al.  ISIDA Property‐Labelled Fragment Descriptors , 2010, Molecular informatics.

[45]  J. Hughes,et al.  Physiochemical drug properties associated with in vivo toxicological outcomes. , 2008, Bioorganic & medicinal chemistry letters.

[46]  W. Patrick Walters,et al.  A guide to drug discovery: Designing screens: how to make your hits a hit , 2003, Nature Reviews Drug Discovery.

[47]  Raman Parkesh,et al.  Structural enrichment of HTS compounds from available commercial libraries , 2012 .

[48]  Vinay Prasad,et al.  Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval , 2017, JAMA internal medicine.

[49]  G. V. Paolini,et al.  Quantifying the chemical beauty of drugs. , 2012, Nature chemistry.

[50]  Asher Mullard,et al.  European Lead Factory opens for business , 2013, Nature Reviews Drug Discovery.

[51]  W. Janzen,et al.  Screening technologies for small molecule discovery: the state of the art. , 2014, Chemistry & biology.

[52]  Nathan Brown,et al.  Plane of Best Fit: A Novel Method to Characterize the Three-Dimensionality of Molecules , 2012, J. Chem. Inf. Model..

[53]  H. Verheij,et al.  Leadlikeness and structural diversity of synthetic screening libraries , 2006, Molecular Diversity.

[54]  Ola Engkvist,et al.  On the Relationship between Molecular Hit Rates in High-Throughput Screening and Molecular Descriptors , 2014, Journal of biomolecular screening.

[55]  Kuo-Chen Chou,et al.  Assessment of chemical libraries for their druggability , 2005, Comput. Biol. Chem..

[56]  Clive Green,et al.  Consolidating a Distributed Compound Management Capability into a Single Installation , 2016, Journal of laboratory automation.

[57]  Mark J Wigglesworth,et al.  Increasing the delivery of next generation therapeutics from high throughput screening libraries. , 2015, Current opinion in chemical biology.

[58]  Stefan Günther,et al.  The Purchasable Chemical Space: A Detailed Picture , 2015, J. Chem. Inf. Model..

[59]  Dragos Horvath,et al.  Generative Topographic Mapping Approach to Chemical Space Analysis , 2017 .

[60]  Stephen D Pickett,et al.  Nuisance Compounds, PAINS Filters, and Dark Chemical Matter in the GSK HTS Collection , 2018, SLAS discovery : advancing life sciences R & D.

[61]  Thierry Kogej,et al.  Big pharma screening collections: more of the same or unique libraries? The AstraZeneca-Bayer Pharma AG case. , 2013, Drug discovery today.

[62]  Valerie J Gillet,et al.  New directions in library design and analysis. , 2008, Current opinion in chemical biology.

[63]  A. Gorse Diversity in medicinal chemistry space. , 2006, Current topics in medicinal chemistry.

[64]  Jens Loesel,et al.  Plate-based diversity subset screening generation 2: an improved paradigm for high-throughput screening of large compound files , 2016, Molecular Diversity.

[65]  Harren Jhoti,et al.  Twenty years on: the impact of fragments on drug discovery , 2016, Nature Reviews Drug Discovery.

[66]  Channa K. Hattotuwagama,et al.  Lead-oriented synthesis: a new opportunity for synthetic chemistry. , 2012, Angewandte Chemie.

[67]  P. Petrone,et al.  Aggregated Compound Biological Signatures Facilitate Phenotypic Drug Discovery and Target Elucidation. , 2016, ACS chemical biology.